Martin Reck, MD, PhD, on NSCLC: Pembrolizumab, Platinum Chemotherapy, and Radiotherapy in Advanced Disease
IASLC 2020 World Conference on Lung Cancer in SingaporeMartin Reck, MD, PhD, of the LungenClinic, discusses the results from KEYNOTE-799, which explored a new strategy to increase the intensity of treatment in patients with unresectable, locally advanced, stage III non–small cell lung cancer (Abstract OA02.03).
Related Videos
Silvia Novello, MD, PhD, on NSCLC: Pharmacogenomics-Driven vs Standard Adjuvant Chemotherapy
Justin F. Gainor, MD, on NSCLC: Study Results on Nivolumab vs Ipilimumab, Bemcentinib Plus Pembrolizumab
Justin F. Gainor, MD, of Massachusetts General Hospital, discusses two key phase II studies on non–small cell lung cancer: nivolumab vs nivolumab plus ipilimumab in EGFR<...
Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib and Patient-Reported Outcomes
Roy S. Herbst, MD, PhD, of Yale University, discusses two key abstracts from the ADAURA trial: the use of osimertinib as adjuvant therapy for resected EGFR-mutated n...
Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked...
Roy S. Herbst, MD, PhD, on LUNG-MAP, Circulating Tumor DNA, and Tissue Molecular Analysis
Roy S. Herbst, MD, PhD, of Yale University, discusses results from the LUNG-MAP Master Protocol, which support the planned use of circulating tumor DNA for enrollment onto LU...
